方盛制药
(603998)
| 流通市值：45.36亿 | | | 总市值：45.36亿 |
| 流通股本：4.39亿 | | | 总股本：4.39亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 462,773,883.82 | 1,746,442,351.5 | 1,253,315,302.11 | 834,248,975.63 |
| 营业收入 | 462,773,883.82 | 1,746,442,351.5 | 1,253,315,302.11 | 834,248,975.63 |
| 二、营业总成本 | 362,507,389.84 | 1,446,723,025.15 | 1,022,150,726.68 | 683,068,914.91 |
| 营业成本 | 114,167,826.78 | 489,544,764.62 | 360,009,924.99 | 247,790,990.68 |
| 税金及附加 | 9,349,155.43 | 34,701,197.47 | 24,810,444.67 | 16,069,167.7 |
| 销售费用 | 163,634,568.64 | 603,524,994.05 | 420,256,241.42 | 280,128,148.16 |
| 管理费用 | 37,286,368.15 | 153,352,871.78 | 100,205,310.56 | 64,926,056.81 |
| 研发费用 | 36,175,845.48 | 154,470,753.53 | 108,080,333.17 | 68,088,518.71 |
| 财务费用 | 1,893,625.36 | 11,128,443.7 | 8,788,471.87 | 6,066,032.85 |
| 其中:利息费用 | 2,338,198.03 | 14,804,356.52 | 11,683,354.73 | 8,158,700.25 |
| 其中:利息收入 | 611,478.15 | 3,981,988.16 | 3,212,328.53 | 2,285,280.76 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 415,272.43 | 1,688,667.73 | 2,241,754.08 | 1,376,986.92 |
| 资产处置收益 | - | 51,391,981.31 | 51,397,589.85 | 20,660,730.85 |
| 资产减值损失(新) | 156,732.8 | -9,768,205.7 | -73,274.91 | -54,625.6 |
| 信用减值损失(新) | -156,888.99 | 311,119.57 | 3,383,200.91 | 4,220,282.52 |
| 其他收益 | 3,029,017.23 | 14,854,258.92 | 11,714,915.47 | 9,729,191.43 |
| 四、营业利润 | 103,710,627.45 | 358,197,148.18 | 299,828,760.83 | 187,112,626.84 |
| 加:营业外收入 | 36,171.36 | 722,848 | 468,594.16 | 147,055.43 |
| 减:营业外支出 | 109,402.98 | 5,679,021.45 | 1,134,858.07 | 766,371.56 |
| 五、利润总额 | 103,637,395.83 | 353,240,974.73 | 299,162,496.92 | 186,493,310.71 |
| 减:所得税费用 | 15,776,646.39 | 50,605,383.66 | 33,810,546.37 | 19,999,230.49 |
| 六、净利润 | 87,860,749.44 | 302,635,591.07 | 265,351,950.55 | 166,494,080.22 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 87,860,749.44 | 302,635,591.07 | 265,351,950.55 | 166,494,080.22 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 88,391,687.93 | 306,387,057.81 | 268,283,287.89 | 169,238,666.58 |
| 少数股东损益 | -530,938.49 | -3,751,466.74 | -2,931,337.34 | -2,744,586.36 |
| 扣除非经常损益后的净利润 | 85,837,601.66 | 248,490,004.5 | 212,675,316.25 | 141,471,405.86 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.2 | 0.7 | 0.61 | 0.39 |
| (二)稀释每股收益 | 0.2 | 0.7 | 0.61 | 0.39 |
| 八、其他综合收益 | -323,131.29 | -197,943.06 | -65,219.22 | - |
| 归属于母公司股东的其他综合收益 | -184,184.84 | -126,434.95 | -60,073.03 | - |
| 九、综合收益总额 | 87,537,618.15 | 302,437,648.01 | 265,286,731.33 | 166,494,080.22 |
| 归属于母公司股东的综合收益总额 | 88,207,503.09 | 306,260,622.86 | 268,223,214.86 | 169,238,666.58 |
| 归属于少数股东的综合收益总额 | -669,884.94 | -3,822,974.85 | -2,936,483.53 | -2,744,586.36 |
| 公告日期 | 2026-04-25 | 2026-04-25 | 2025-10-24 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |